Penserra Capital Management’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Penserra Capital Management’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,360	Closed	-$7K	–	1339
2022 Q2	$7K	Sell	2,360 -182	-7%	-$1.11K	﹤0.01%	1330
2022 Q1	$18K	Sell	2,542 -775	-23%	-$7.62K	﹤0.01%	1294
2021 Q4	$54K	Buy	+3,317	New	+$38.6K	﹤0.01%	1008

Other funds holding PRDS

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FCOMV

Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

Penserra Capital Management's PRDS Position: Q3 2022 in Review

Penserra Capital Management sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2022, closing a stake of 2,360 shares — an estimated $7K sold.

Penserra Capital Management first reported a position in PRDS in Q4 2021 and held it in 3 quarters. The position peaked at $54K in Q4 2021. 68 funds tracked by Wall St. Rank hold PRDS as of Q3 2022.

Penserra Capital Management reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Penserra Capital Management sold 2,360 Pardes Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $7K.
Penserra Capital Management first reported a position in Pardes Biosciences, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
Penserra Capital Management's Pardes Biosciences, Inc. Common Stock position peaked at $54K in Q4 2021.
68 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.